PharmaJet Presents Needle-free delivery of COVID-19 Vaccines and Beyond at World Vaccine Congress – Europe
By: Colorado BioScience Association Date: 10/13/2021
Superior immunogenicity expands vaccine development with Needle-free delivery
PharmaJet®, the maker of innovative, needle-free injection technology, announced that their latest partnerships and research results will be presented at the World Vaccine Congress – Europe on October 21. The presentation, entitled Needle-free Delivery: COVID-19 Vaccines and Beyond, is being presented by Erin K. Spiegel, PhD, Vice President, Clinical & Regulatory Affairs at PharmaJet, Inc.
The PharmaJet Needle-free Injection Systems (NFIS) are the first and only needle-free injection devices to pass World Health Organization pre-qualification standards (PQS) among other regulatory clearances. The devices are commercially validated for both 0.5mL Intramuscular/Subcutaneous (IM/SC) or 0.1mL Intradermal (ID) route. With PharmaJet NFIS delivery, the immunogenicity of nucleic acid vaccines across multiple indications was enhanced. Additionally, the improved patient and caregiver experience has resulted in increased vaccine compliance, safety, and comfort.
The systems have been used in multiple clinical studies in the vaccine development sector for COVID-19, Influenza, HPV, Zika, cancer, and others, and several are now entering commercialization phase. Most recently, the COVID-19 DNA vaccine developed by Zydus Cadila (ZYCOV-D) has received Emergency Use Authorization in India for individuals 12 years and up, delivered exclusively with the PharmaJet Tropis® ID system. It is the first DNA vaccine to receive approval for use in humans. Other partners including BioNet Asia, GeneOne and DioSynVax/University of Cambridge are planning or continuing clinical trials.
Find out more in the press release.